Treatment Identity And Randomization Codes

From Treatment Codes to Treatment Identity

In a blinded trial, a result may be reported for codes such as A and B without saying which code is the investigational treatment and which is the control. A treatment key supplies that missing mapping. Applying it does not change participants’ observed outcomes or the numerical summaries already calculated; it changes what those summaries mean in treatment terms. A contrast that was “A minus B” becomes “active treatment minus control” only after the key establishes which code denotes each treatment.

It is useful to distinguish two records that are sometimes both informally called the randomization code. The allocation record links a participant to an assigned code. The treatment key links each code to a treatment identity. The first might say participant 001 was assigned A; the second might say A is the investigational treatment. Having one record does not logically supply the other.

In a two-arm trial, the key has one of two possible mappings if the code labels alone are known: A may be active treatment and B control, or B may be active treatment and A control. The data values do not tell us which mapping is correct. That is supplied by the trial’s authorized key, not inferred from which arm has a larger or more favorable outcome.

What Applying the Key Changes

Suppose the endpoint is a change score in points, with larger values representing greater improvement. Let \(\bar{x}_A\) and \(\bar{x}_B\) be the sample means for the two coded groups. The coded contrast, defined here as A minus B, is

If the key says A is active treatment and B is control, the active-minus-control estimate is \(\hat{\Delta}=\hat{\Delta}_{A-B}\). If the key says B is active treatment and A is control, the active-minus-control estimate is \(\hat{\Delta}=-\hat{\Delta}_{A-B}\). The sign is therefore not interpretable as benefit or harm until the mapping and the endpoint direction are both known.

A key is a relabeling, not a recalculation of the endpoint. The number of observations in each coded group, each group’s mean and standard deviation, and the pooled mean remain the same after relabeling. The identity attached to each group changes, and any treatment contrast whose direction is tied to identity may change sign.

The Mapping and the Direction of the Contrast

The relabeling can be shown directly. Let the two coded means be \(m_A\) and \(m_B\). There are two possible key mappings. Under mapping 1, active treatment is A, so the active-minus-control contrast is \(m_A-m_B\). Under mapping 2, active treatment is B, so it is \(m_B-m_A\). Since \(m_B-m_A=-(m_A-m_B)\), the identified contrast reverses sign when the mapping reverses.

By contrast, the pooled mean is unchanged. With group sizes \(n_A\) and \(n_B\), it is

Swapping the treatment names does not change either term in this expression: the A observations still contribute \(n_A\bar{x}_A\), and the B observations still contribute \(n_B\bar{x}_B\). Only their treatment names change. This distinction is useful when checking a report: summaries that combine both arms should not change solely because the treatment key was applied, while an identity-oriented contrast may change its sign.

Tracing the Key Through a Small Data Set

A transparent conversion can be checked from the allocation record through the coded summaries to the identified result. For example, a data extract may contain a participant identifier, an assigned code, and an endpoint value. The treatment key is then applied to the code column. It should not be applied by guessing from outcomes or by changing the endpoint values. The following example shows the bookkeeping on a small hypothetical data set.

Assumptions, Checks, and Failure Modes

The mathematical conversion is simple, but its validity depends on correct operational details. The code labels must be mapped by the correct, authoritative key for the relevant trial and data version. Each code must map to one treatment identity, and the analysis must use the intended contrast direction. If a trial has more than one stage, protocol version, or code system, do not assume that an old key applies to every record. Verify which mapping governs the records being summarized.

A useful audit follows the data path explicitly: verify the allocation code for each record, verify the code-to-treatment mapping, tabulate the resulting treatment-group counts, and independently recompute at least one group summary and the planned contrast. The identified group counts should match the coded counts after relabeling. A group count that changes during a mere key application is a warning of a data-processing or filtering error.

Other warning signs include an effect estimate whose sign does not match the stated contrast direction, treatment names attached to the wrong coded column, and summaries from different key versions appearing in the same report. A numerical result may be arithmetically correct yet incorrectly identified. Check the mapping before interpreting whether an estimate favors one treatment.

The conversion assumes that the treatment identities and the endpoint definition are already fixed for the records being interpreted. It does not repair missing outcomes, incorrect allocations, endpoint coding errors, or an estimand that no longer matches the trial question. It also does not by itself justify a causal conclusion or provide an inferential analysis; those require the relevant design, estimand, and statistical methods.

Why Access to the Key Matters

A person who can connect A and B to treatment identities can interpret arm-specific results in treatment terms, even if reports continue to use code labels. Thus, masking is not determined only by whether a document prints the words “active” and “control”; it also depends on whether a recipient can access the mapping. Conversely, a report can preserve a coded presentation for some recipients while an authorized analyst uses the key to identify the same results.

The main alternatives differ in what can be interpreted. A pooled summary combines both arms and does not, by itself, identify an arm-specific treatment contrast. A coded arm-specific summary shows differences between A and B but leaves the treatment identity unresolved. An identified arm-specific summary applies the key and supports statements about active treatment versus control. These are different information states, not different sets of observed outcomes.

A common mistake is to treat “A had the larger mean” as evidence that A must be active, or to describe A minus B as the treatment effect without checking the key. That reasoning uses the observed result to guess the treatment identity and can invert the interpretation. The correction is to obtain the authorized mapping, state the contrast direction explicitly, and only then translate coded summaries into treatment-identified conclusions.